India · Delayed Price · Currency is INR Torrent Pharmaceuticals Statistics
Total Valuation
NSE:TORNTPHARM has a market cap or net worth of INR 1.74 trillion. The enterprise value is 1.85 trillion.
| Market Cap | 1.74T |
| Enterprise Value | 1.85T |
Important Dates
The last earnings date was Friday, October 23, 2026.
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
| Current Share Class | 380.37M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.17% |
| Shares Change (QoQ) | -0.15% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 19.75% |
| Float | 146.84M |
Valuation Ratios
The trailing PE ratio is 77.20 and the forward PE ratio is 59.71.
| PE Ratio | 77.20 |
| Forward PE | 59.71 |
| PS Ratio | 9.97 |
| PB Ratio | 9.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 48.64 |
| P/OCF Ratio | 39.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.05, with an EV/FCF ratio of 51.76.
| EV / Earnings | 86.89 |
| EV / Sales | 10.61 |
| EV / EBITDA | 32.05 |
| EV / EBIT | 47.85 |
| EV / FCF | 51.76 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.32 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 2.45 |
| Debt / FCF | 3.96 |
| Interest Coverage | 4.36 |
Financial Efficiency
Return on equity (ROE) is 15.65% and return on invested capital (ROIC) is 9.64%.
| Return on Equity (ROE) | 15.65% |
| Return on Assets (ROA) | 8.02% |
| Return on Invested Capital (ROIC) | 9.64% |
| Return on Capital Employed (ROCE) | 10.53% |
| Weighted Average Cost of Capital (WACC) | 4.97% |
| Revenue Per Employee | 9.53M |
| Profits Per Employee | 1.16M |
| Employee Count | 18,258 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.49 |
Taxes
In the past 12 months, NSE:TORNTPHARM has paid 7.14 billion in taxes.
| Income Tax | 7.14B |
| Effective Tax Rate | 25.38% |
Stock Price Statistics
The stock price has increased by +27.48% in the last 52 weeks. The beta is 0.14, so NSE:TORNTPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +27.48% |
| 50-Day Moving Average | 4,815.78 |
| 200-Day Moving Average | 4,508.03 |
| Relative Strength Index (RSI) | 39.72 |
| Average Volume (20 Days) | 297,935 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:TORNTPHARM had revenue of INR 174.00 billion and earned 21.24 billion in profits. Earnings per share was 59.12.
| Revenue | 174.00B |
| Gross Profit | 131.99B |
| Operating Income | 38.58B |
| Pretax Income | 28.13B |
| Net Income | 21.24B |
| EBITDA | 57.12B |
| EBIT | 38.58B |
| Earnings Per Share (EPS) | 59.12 |
Balance Sheet
The company has 29.86 billion in cash and 141.07 billion in debt, with a net cash position of -111.21 billion.
| Cash & Cash Equivalents | 29.86B |
| Total Debt | 141.07B |
| Net Cash | -111.21B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 183.73B |
| Book Value Per Share | 483.41 |
| Working Capital | 25.34B |
Cash Flow
In the last 12 months, operating cash flow was 44.37 billion and capital expenditures -8.70 billion, giving a free cash flow of 35.66 billion.
| Operating Cash Flow | 44.37B |
| Capital Expenditures | -8.70B |
| Depreciation & Amortization | 18.54B |
| Net Borrowing | 112.98B |
| Free Cash Flow | 35.66B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.85%, with operating and profit margins of 22.17% and 12.21%.
| Gross Margin | 75.85% |
| Operating Margin | 22.17% |
| Pretax Margin | 16.17% |
| Profit Margin | 12.21% |
| EBITDA Margin | 32.83% |
| EBIT Margin | 22.17% |
| FCF Margin | 20.50% |
Dividends & Yields
This stock pays an annual dividend of 38.00, which amounts to a dividend yield of 0.83%.
| Dividend Per Share | 38.00 |
| Dividend Yield | 0.83% |
| Dividend Growth (YoY) | 18.75% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 69.05% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.17% |
| Shareholder Yield | -5.33% |
| Earnings Yield | 1.30% |
| FCF Yield | 2.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:TORNTPHARM is 5,472.79, which is 19.91% higher than the current price. The consensus rating is "Buy".
| Price Target | 5,472.79 |
| Price Target Difference | 19.91% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 21.74% |
| EPS Growth Forecast (3Y) | 20.93% |
Stock Splits
The last stock split was on July 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jul 8, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |